- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.04. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024 | 1 | GlobeNewswire (USA) | ||
| 19.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 - 27, 2024 | 1 | GlobeNewswire (USA) | ||
| 12.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum | 1 | GlobeNewswire (USA) | ||
| 07.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 56 | GlobeNewswire (Europe) | LOWELL, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
| 04.03. | Earnings call: Rapid Micro Biosystems sees 45% revenue growth in Q4 | 1 | Investing.com | ||
| 01.03. | RAPID MICRO BIOSYSTEMS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 01.03. | RAPID MICRO BIOSYSTEMS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 01.03. | Rapid Micro Biosystems Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 01.03. | Rapid Micro Biosystems revenue jumps 45% in Q4, but outlook trails consensus | 1 | Investing.com | ||
| 01.03. | Rapid Micro Biosystems: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 01.03. | Rapid Micro Biosystems GAAP EPS of -$0.26 beats by $0.04, revenue of $6.34M beats by $0.19M | 1 | Seeking Alpha | ||
| 01.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance | 203 | GlobeNewswire (Europe) | Reports fourth quarter 2023 total revenue of $6.3 million, representing 45% growth compared to fourth quarter 2022 Reports 2023 revenue of $22.5 million, representing 31% growth compared to 2022 Delivered... ► Artikel lesen | |
| 01.03. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.02. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Participate in Upcoming Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 20.02. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024 | 3 | GlobeNewswire (USA) | ||
| 02.02. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.01. | Rapid Micro Biosystems up on prelim Q4 results, sterility kit launch date | 1 | Reuters | ||
| 10.01. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.01. | Rapid Micro Biosystems reports 30% annual revenue growth | 2 | Investing.com | ||
| 10.01. | Rapid Micro Biosystems issues Q4 and FY23 guidance | 1 | Seeking Alpha |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,535 | -5,83 % | EQS-NVR: Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Epigenomics AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Epigenomics AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,824 | -3,06 % | Kaufen nach Abverkauf? Defence Therapeutics, Infineon Technologies, Super Micro Computer, TSMC Aktie | Die Marktteilnehmer waren nach den starken Kursrückgängen von Dow Jones und DAX sehr nervös. Schon panikartig wurden in der Nacht zu Freitag viele Aktien und damit auch Indizes abverkauft. Erst in den... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,990 | +15,07 % | Ginkgo Bioworks surges as much as 31%, though pares gains | ||
| BEAM THERAPEUTICS | 22,050 | +3,23 % | Expert Ratings For Beam Therapeutics | ||
| ONCOLYTICS BIOTECH | 1,030 | +1,98 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,200 | +0,99 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| ARCTURUS THERAPEUTICS | 26,630 | +0,30 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,848 | +8,01 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 8,830 | +0,46 % | SIGA Technologies - Positive signals abound | SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 14,740 | 0,00 % | Merrimack Pharmaceuticals, Inc. Reports Full Year 2023 Financial Results | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,370 | +1,70 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,260 | +1,95 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 8,600 | +2,99 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy (Epinephrine Nasal Spray) | Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected... ► Artikel lesen | |
| BIO-PATH | 2,850 | +6,34 % | Bio-Path files to sell 484K shares of common stock for holders | ||
| BIOMEA FUSION | 10,750 | -0,28 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen RAPID MICRO BIOSYSTEMS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,964 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
